Zaemes Jacob, Gibney Geoffrey T
Department of Medicine, Division of Medical Oncology, Harvard Medical School, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA.
Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, USA.
Surg Clin North Am. 2025 Jun;105(3):681-690. doi: 10.1016/j.suc.2025.03.004.
Cellular therapy has been an evolving therapeutic approach in advanced melanoma over the past 40 y. The first tumor infiltrating lymphocyte (TIL) therapy, lifileucil, was Food and Drug Administration-approved in 2024 for patients with metastatic melanoma who have previously been treated with an anti-PD-1 therapy and BRAF inhibitor (BRAF V600 mutant disease). Further clinical development of TIL therapy will hopefully lead to safer and more effective strategies. Cellular therapy in melanoma has also expanded beyond TIL therapy with anti-tumor activity demonstrated for TCR-transduced T-cell products and T-cell engager bi-specific agents that target melanoma antigens.
在过去40年里，细胞疗法一直是晚期黑色素瘤不断发展的治疗方法。首个肿瘤浸润淋巴细胞（TIL）疗法——利菲妥昔，于2024年获美国食品药品监督管理局批准，用于曾接受过抗PD-1疗法和BRAF抑制剂（BRAF V600突变疾病）治疗的转移性黑色素瘤患者。TIL疗法的进一步临床开发有望带来更安全、更有效的策略。黑色素瘤的细胞疗法也已超越TIL疗法，TCR转导的T细胞产品和靶向黑色素瘤抗原的双特异性T细胞衔接剂均显示出抗肿瘤活性。
